Mucormycosis News and Research

RSS
Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

Antifungal drug resistance evoked through RNAi-dependent epimutations

Antifungal drug resistance evoked through RNAi-dependent epimutations

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Study: Investigational drug effective in reducing mucormycosis infections

Study: Investigational drug effective in reducing mucormycosis infections

CotH protein mediates fungal invasion of host cells during mucormycosis

CotH protein mediates fungal invasion of host cells during mucormycosis

Research finding could lead to development of vaccine and therapies for mucormycosis

Research finding could lead to development of vaccine and therapies for mucormycosis

Apophysomyces fungus kills 5 people following a massive Joplin tornado

Apophysomyces fungus kills 5 people following a massive Joplin tornado